Targeting MAO-B with Small-Molecule Inhibitors: A Decade of Advances in Anticancer Research (2012–2024)
Molecules · 2024
DOI: 10.3390/molecules30010126 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, 2024. Verfasst von Iyman Alsaad und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, School of Pharmacy, University of Jordan, Amman 11942, Jordan. Hauptthemen laut MEDLINE: Monoamine Oxidase Inhibitors, Monoamine Oxidase, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: al-zaytoonah university, Deanship of Scientific Research at Al-Zaytoonah University of Jordan.
Abstract (Originalsprache)
Monoamine oxidase B (MAO-B) is a key enzyme in the mitochondrial outer membrane, pivotal for the oxidative deamination of biogenic amines. Its overexpression has been implicated in the pathogenesis of several cancers, including glioblastoma and colorectal, lung, renal, and bladder cancers, primarily through the increased production of reactive oxygen species (ROS). Inhibition of MAO-B impedes cell proliferation, making it a potential therapeutic target. Various monoamine oxidase B inhibitors have shown promise in inhibiting tumor growth and inducing apoptosis across different cancer types. In this review, we investigate MAO-B network biology, which highlighted glycolysis pathways as notable links between MAO-B and cancer. Further molecular modeling analysis illustrated the basis of MAO-B ligand binding, revealing a hydrophobic binding pocket, with key residues such as Tyr398 and Tyr435 playing crucial roles in substrate oxidation. MAO-B inhibitors that were reportsed in the literature (2012–2024) and their potential application in cancer therapy were discussed, highlighting key molecular scaffolds, such as propargyl analogs of phenyl alkyl amines, hydrazine derivatives, cyclopropylamine derivatives, MAO-B activated pro-drugs, and natural phenylpropanoid derivatives. The reported literature underscores the therapeutic potential of MAO-B inhibitors as versatile anticancer agents, warranting further investigation to optimize their efficacy and specificity across various malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, School of Pharmacy, University of Jordan, Amman 11942, Jordan.
- Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, P.O. Box 130, Amman 11733, Jordan.
- Laboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
- Jordan CDC, Amman 11118, Jordan.
ORCID-Profile: Dima A Sabbah, Rima Hajjo, Sanaa K Bardaweel
Förderung
- al-zaytoonah university
- Deanship of Scientific Research at Al-Zaytoonah University of Jordan
Zitieren
APA
Alsaad, I., Abdel Rahman, D. M. A., Al-Tamimi, O., Alhaj, S. A., Sabbah, D. A., Hajjo, R., & Bardaweel, S. K. (2024). Targeting MAO-B with Small-Molecule Inhibitors: A Decade of Advances in Anticancer Research (2012–2024). Molecules. https://doi.org/10.3390/molecules30010126
Vancouver
Alsaad I, Abdel Rahman DMA, Al-Tamimi O, Alhaj SA, Sabbah DA, Hajjo R, et al. Targeting MAO-B with Small-Molecule Inhibitors: A Decade of Advances in Anticancer Research (2012–2024). Molecules. 2024. doi:10.3390/molecules30010126
BibTeX
@article{Alsaad2024,
author = {Alsaad, Iyman and Abdel Rahman, Diana M A and Al-Tamimi, Ola and Alhaj, Shayma'a A and Sabbah, Dima A and Hajjo, Rima and Bardaweel, Sanaa K},
title = {Targeting MAO-B with Small-Molecule Inhibitors: A Decade of Advances in Anticancer Research (2012–2024)},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules30010126}
}
EUVIMED